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lieved to be logical have been disproved. Furthermore, these results were not consistent with findings from the Multicenter Automatic Defibrillator
Implantation Trial II (MADIT-II) and the Defibrillators in Non-Ischemic Cardiomyopathy Treatment
Evaluation (DEFINITE), in which patients with class
III disease benefited at least as much, on a relative
scale, as did those with class II disease. This issue
remains unresolved.
Dr. Patwala and colleagues wonder whether
amiodarone–digoxin interactions diminished survival in the amiodarone group. Although we did
not record digoxin levels, the data and safety monitoring board monitored the trial carefully, and
there were no adverse-event data to suggest such a
problem in the amiodarone group. In addition, the
mechanisms of death in the amiodarone group did
not include a rise in the incidence of sudden death
due to arrhythmia, which one might expect as a
consequence of digoxin toxicity.
The final issue raised by these correspondents is
that the frequency of beta-blocker use increased to
a lesser extent in the amiodarone group than in the
other groups during the trial. Although the increase
over time was smaller, the rate of beta-blocker
use was high in all trial groups. More important,
those treated with amiodarone and beta-blockers
had a slightly (not significantly) worse outcome
than those in the amiodarone group who were not
treated with beta-blockers, as shown in Figure 4 of
our article. Thus, we maintain that amiodarone
confers no survival benefit on patients when used
for primary prevention.
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dr. kadish replies: Dr. Nash notes that the median

age of the patients in SCD-HeFT was about 60 years
and thus suggests that extrapolating data from
SCD-HeFT to the Medicare population may not be
appropriate. It should be noted that other trials of
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ICD therapy in patients with coronary disease, including the Multicenter Unsustained Tachycardia
Trial1 and MADIT-II,2 involved patients with an average age that was closer to 65 and showed that
ICD therapy was associated with a benefit similar
to or greater than that seen in SCD-HeFT. In addition, there was no significant difference in the
ICD-associated benefit between those 65 or older
and those younger than 65 in SCD-HeFT and
DEFINITE.3 As the average life expectancy approaches 80 years and as the quality of life among
elderly patients increases, it would not be appropriate to withhold lifesaving therapy from patients
older than 65 because of a preconceived notion that
it will not offer them a benefit.
Dr. Mack performs an estimated cost-effectiveness analysis and concludes that ICD therapy will
cost $86,000 per year of life saved and that the
amount spent on defibrillators means that other
services will be withheld. A preliminary analysis of
data from SCD-HeFT shows a much lower cost per
life-year saved.4 Overall, Medicare spending is determined annually by Congress, and information
on actual health care costs is available for budgeting. No hard ceiling on spending has been established. Finally, subgroup analysis or pooling of data
is attractive to generate hypotheses but does not
serve as an evidence-based approach to determine
therapy. It is true that certain subgroups who benefit less than others from ICD implantation may be
identified, and it is hoped that the prospective registry mandated by the Centers for Medicare and
Medicaid Services will help provide additional information about which patients will benefit most
from ICD therapy. However, before such data are
available, the best guide for clinicians with regard
to ICD implantation remains the inclusion criteria
in clinical trials.
Alan H. Kadish, M.D.
Northwestern Memorial Hospital
Chicago, IL 60611
a-kadish@northwestern.edu
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